Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 19:3:99-106.
doi: 10.2147/HMER.S22309. eCollection 2011.

Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program

Guillermo Cervio  1 , Julio Trentadue  2 , Daniel D'Agostino  3 , Carlos Luque  4 , Mariano Giorgi  5 , Judith Armoni  6 , Roberto Debbag  6
Affiliations

Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program

Guillermo Cervio et al. Hepat Med. .

Abstract

Introduction: Hepatitis A virus (HAV) infection is a vaccine-preventable disease. The most severe complication in children is fulminant hepatic failure (FHF), estimated to occur in 0.4% of cases; patients with FHF often require a liver transplant (LT). Following another outbreak of HAV infection in Argentina during 2003-2004, a one-dose HAV universal immunization (UI) program was started in 2005, resulting in a reduction in the incidence of HAV infection. We have investigated the impact of HAV UI on the trends in the occurrence of FHF and LT in children.

Methods: All pediatric cases of FHF admitted to four pediatric centers in Buenos Aires during March 1993-July 2005 were retrospectively reviewed, and data of cases during August 2005-December 2008 were collected. Information about demography, HAV infections and vaccination status, diagnostic data for FHF using the Pediatric Acute Liver Failure criteria, clinical laboratory results, encephalopathy, the severity of liver disease using the Pediatric End Stage Liver Disease score, assessment of patients on the LT waiting list using King's College Criteria for LT, treatment given for FHF (pre- and post-transplant), and clinical outcome were collected using a case report form. The frequency and outcomes of HAV-associated FHF and LT cases before and after UI were analyzed.

Results: During the pre-immunization period, March 1993-July 2005, 54.6% (N = 165) of FHF cases were caused by HAV; HAV-associated FHF cases peaked during 2003-2004. During the post-immunization period, August 2005-December 2008, only 27.7% (N = 18) of FHF cases were caused by HAV infection; only one of these patients had received the HAV vaccine (one dose only). The number of HAV-associated FHF cases decreased from 2005, and no cases were reported from November 2006-December 2008. Multivariate analyses showed that the association of FHF with HAV infection rather than other etiologies decreased with increasing age (P = 0.03), UI against HAV (P = 0.002), and anti-actin antibodies (P = 0.002), and increased with increasing weight (P = 0.0004).

Conclusions: The number of children with HAV-associated FHF in Argentina has strongly decreased since the initiation of the UI program. Further monitoring is required to confirm the long-term health and economic benefits of UI against HAV infection.

Keywords: fulminant hepatic failure; hepatitis A vaccine; immunization.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of fulminant hepatic failure cases caused by hepatitis A virus (HAV) or other etiologies each year. Other etiologies included cases where the cause was indeterminate, autoimmune disease, Wilson disease, or Amanita phalloides. There were similar numbers of cases of indeterminate cause pre- and post-HAV universal immunization.
Figure 2
Figure 2
Causes by etiology of cases of fulminant hepatic failure (FHF) during the study. Abbreviations: UI, universal immunization; HAV, hepatitis A virus.
Figure 3
Figure 3
Coverage rate for hepatitis B virus (HVB) and hepatitis A virus (HAV) vaccination in Argentina 2002–2008 (HVB 12 Hs - coverage rate of HVB at 12 hours of life; HVB 3º D - coverage rate of third HVB dose; HVA 12 m - coverage rate of HA virus at 12 month of age). Data source: Ministry of Health, Argentina.
See this image and copyright information in PMC

References

    1. World Health Organization Hepatitis A vaccines Wkly Epidemiol Rec 200075538–44.Available from: http://www.who.int/docstore/wer/pdf/2000/wer7505.pdfAccessed April 13, 2010
    1. Yeung LT, Roberts EA. Current issues in the management of paediatric viral hepatitis. Liver Int. 2010;30(1):5–18. - PubMed
    1. Ciocca ME, Ramonet MD, Cuarterolo ML, et al. Acute liver failure in children: experience with 210 patients. J Pediatr Gastroenterol Nutr. 2004;39(Suppl 1):S31.
    1. Debbag R, Sarquis C, Bes D, Fernandez Torroija M, Ciocca M, Speranza A.10 years experience in fulminant hepatic failure due to hepatitis A. Costs and evolution [Abstract 42.026] Program and abstracts of the 11th Congress of the International Society for Infectious Diseases2004 Mar 4–7Cancun, MexicoAvailable from: http://www.isid.org/Downloads/11th_ICID_Abstracts.pdfAccessed April 13, 2010
    1. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine. 2000;18(Suppl 1):S71–S74. - PubMed